Discover what's new.

Access the latest news, business developments, company updates, industry trends, events and more.

| By Kelley Gipson

Bilenker, Engelman create Treeline Biosciences

Josh Bilenker, M.D., and Jeff Engelman M.D., Ph.D., have joined forces to create a new cancer biotech, tapping their combined considerable experience to find new...

| By Kelley Gipson

CaroGen awarded $3 million Phase 2b SBIR grant

CaroGen Corporation has been awarded a $3 million Phase 2b SBIR grant from the National Institutes of Health (NIH) to advance its lead clinical candidate...

| By Kelley Gipson

Astrocyte raises $6M re stroke and TBI treatments

Astrocyte Pharmaceuticals reports the completion of a Series A financing that raised $6.0M. Astrocyte is progressing its lead development candidate AST-004 to address the unmet...

| By Kelley Gipson

BioCT welcomes Cynthia Green to Board of Directors

BioCT welcomes Cynthia D. Green, PhD, MBA, to its Board of Directors. Cyndi is currently Managing Director at Connecticut Innovations, the state’s strategic venture capital arm...

| By Kelley Gipson

UConn research develops Zika virus vaccine

UConn researcher Paulo Verardi, associate professor of pathobiology and veterinary science in the College of Agriculture, Health and Natural Resources, has demonstrated the success of...

| By Kelley Gipson

InveniAI® in collaboration with Shionogi & Co.

InveniAI® reports a multi-target drug discovery collaboration with Shionogi & Co. The multi-year collaboration will combine InveniAI’s AI platform, AlphaMeld®, to research and validate targets...

| By Kelley Gipson

MediSynergics receives USPTO Notice of Allowance

MediSynergics reports that the company has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for its ketamine derivative patent...

| By Kelley Gipson

CaroGen targeting breakthrough immunotherapy

CaroGen’s lead product is an immunotherapy that targets Hepatitis B. The company is also working on immunotherapies for ovarian cancer and for colorectal cancer. Bijan Almassian is...